Novartis nabs Merck exec Bruno Strigini to head up oncology business

Bruno Strigini

Novartis ($NVS) wooed one of Merck's ($MRK) top executives to take the helm at its oncology unit. The Swiss drugmaker tapped Bruno Strigini, president of Merck's European and Canadian operations, to take over for Alessandro Riva, who's been interim chief of Oncology Development and Medical Affairs. Riva temporarily replaced Hervé Hoppenot, who jumped ship earlier this year for a CEO job at Novartis development partner Incyte ($INCY). Release

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.